Region-dependent regulatioin of Tau phosphorylation in a mouse model of tauopathy
- 1Johns Hopkins University
Abstract
Hyperphosphorylation of Tau promotes its aggregation and neurofibrillary tangle (NFT) formation, contributing to neuronal dysfunction and neurodegeneration in diseases such as Alzheimer's Disease (AD) and AD-related dementias (ADRDs). However, the mechanisms underlying dysregulated Tau phosphorylation under pathological contexts remain unclear. Glycerophosphodiester phosphodiesterase 2 (GDE2) is a six-transmembrane enzyme that acts at the cell surface to cleave the glycosylphosphatidylinositol (GPI)-anchor that tethers a subclass of proteins to the membrane. Here, we show that in the PS19 tauopathy mouse model, GDE2 disruption modulates Tau phosphorylation, decreasing Tau's propensity for aggregation by regulating local kinase environments in a region-specific manner. In the cortex, GDE2 ablation in PS19 mice (PS19;Gde2KO) transiently delays Tau phosphorylation at pro-aggregation sites (Serine (S)202/Threonine (T)205, T212, and S396) and accelerates phosphorylation at the anti-aggregation site S262, with a marked reduction in S202/T205 and T212 phosphorylation at 6 months. While Tau phosphorylation at S202/T205 is similarly delayed in the hippocampus, PS19;Gde2KO animals show increased phosphorylation at S262 at 6 months. Consistent with these changes, AKT and Glycogen Synthase Kinase-3 / {beta} (GSK3 / {beta}) activities are decreased in the cortex, while AKT activity is increased in the hippocampus, with no changes in protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) activity. Primary cortical neurons from PS19;Gde2KO animals showed reduced Tau phosphorylation at S202/T205, implying cell-autonomous roles for neuronal GDE2 in this process. GDE2 overexpression in heterologous SH-SY5Y cells increased Tau phosphorylation at S202/T205, while a catalytically inactive form of GDE2 did not, suggesting that GDE2 regulation of target GPI-anchored protein surface activity is required to modulate Tau phosphorylation. Taken together, our study identifies GDE2 as a component of the complex regulatory network that controls Tau phosphorylation in the context of tauopathy and provides insight into putative pathways relevant to Tau pathologies observed in disease.
Related
- In vivo positron emission tomography imaging of mitochondrial abnormalities in a mouse model of tauopathy
- BIN1 recovers tauopathy-induced long-term memory deficits in mice and interacts with Tau through Thr348 phosphorylation
- Neuroprotective effect of mitochondrial translocator protein ligand in a mouse model of tauopathy
- The sphingosine-1-phosphate receptor functional antagonist fingolimod exacerbates neuroinflammation and tau pathology in a mouse model of tauopathy
- Exacerbation of neurodegeneration by a metabolically engineered bacterium in a mouse model of tauopathy
BibTeX
@misc{jimenezornelas2026regiondependent,
title = {{Region-dependent regulatioin of Tau phosphorylation in a mouse model of tauopathy}},
author = {C. Jimenez-Ornelas and S. Sockanathan},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.14.751492},
url = {https://www.biorxiv.org/content/10.64898/2026.09.14.751492v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Region-dependent regulatioin of Tau phosphorylation in a mouse model of tauopathy
AU - C. Jimenez-Ornelas
AU - S. Sockanathan
PY - 2026
DA - 2026/09/14
PB - bioRxiv
DO - 10.64898/2026.09.14.751492
UR - https://www.biorxiv.org/content/10.64898/2026.09.14.751492v1
AB - Hyperphosphorylation of Tau promotes its aggregation and neurofibrillary tangle (NFT) formation, contributing to neuronal dysfunction and neurodegeneration in diseases such as Alzheimer's Disease (AD) and AD-related dementias (ADRDs). However, the mechanisms underlying dysregulated Tau phosphorylation under pathological contexts remain unclear. Glycerophosphodiester phosphodiesterase 2 (GDE2) is a six-transmembrane enzyme that acts at the cell surface to cleave the glycosylphosphatidylinositol (GPI)-anchor that tethers a subclass of proteins to the membrane. Here, we show that in the PS19 tauopathy mouse model, GDE2 disruption modulates Tau phosphorylation, decreasing Tau's propensity for aggregation by regulating local kinase environments in a region-specific manner. In the cortex, GDE2 ablation in PS19 mice (PS19;Gde2KO) transiently delays Tau phosphorylation at pro-aggregation sites (Serine (S)202/Threonine (T)205, T212, and S396) and accelerates phosphorylation at the anti-aggregation site S262, with a marked reduction in S202/T205 and T212 phosphorylation at 6 months. While Tau phosphorylation at S202/T205 is similarly delayed in the hippocampus, PS19;Gde2KO animals show increased phosphorylation at S262 at 6 months. Consistent with these changes, AKT and Glycogen Synthase Kinase-3 / {beta} (GSK3 / {beta}) activities are decreased in the cortex, while AKT activity is increased in the hippocampus, with no changes in protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) activity. Primary cortical neurons from PS19;Gde2KO animals showed reduced Tau phosphorylation at S202/T205, implying cell-autonomous roles for neuronal GDE2 in this process. GDE2 overexpression in heterologous SH-SY5Y cells increased Tau phosphorylation at S202/T205, while a catalytically inactive form of GDE2 did not, suggesting that GDE2 regulation of target GPI-anchored protein surface activity is required to modulate Tau phosphorylation. Taken together, our study identifies GDE2 as a component of the complex regulatory network that controls Tau phosphorylation in the context of tauopathy and provides insight into putative pathways relevant to Tau pathologies observed in disease.
ER -